Digestive track Cancer (poorly differentiated) death 4X less likely if 2,000 IU of vitamin D – RCT
Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial.
Nutrients. 2019 Oct 22;11(10). pii: E2547. doi: 10.3390/nu11102547.
Yonaga H1,2, Okada S3, Akutsu T4, Ohdaira H5, Suzuki Y6, Urashima M7.
* original study
1. Vitamin D Receptor and Cancers
1. Items in both categories Vitamin D Receptor and Cancer - Colon:
{category}
1. Items in both categories Vitamin D Receptor and Cancer
{category}
1. Items in both categories Vitamin D Receptor and Cancer - other:
{category}
📄 Download the PDF from VitaminDWiki
Mainly Stomach Cancers
Some coauthors of this study previously performed the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2,000 IU/day) in 417 patients with stage I to III digestive tract cancer from the esophagus to the rectum who underwent curative surgery (UMIN000001977).
We conducted a post-hoc analysis of the AMATERASU trial to explore the effects of modification of vitamin D supplementation by histopathological characteristics on survival. Among patients with poorly differentiated adenocarcinoma, the 5-year relapse-free survival rate of patients supplemented with vitamin D was 91% compared with 63% in the placebo group (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.08 to 0.78; P = 0.017; P for interaction = 0.023).
Similarly, the 5-year overall survival rate was 92% in the vitamin D group compared with 72% in the placebo group ( HR, 0.25 ; 95%CI, 0.07 to 0.94; P = 0.040; P for interaction = 0.012).
In contrast, there were no significant effects in other histopathological characteristics between vitamin D and placebo groups. These findings generated the hypothesis that oral vitamin D supplementation may improve both relapse-free survival and overall survival in a subgroup of patients with poorly differentiated adenocarcinoma.
From the web
“The poorly differentiated neuroendocrine carcinoma subtype is characterized by its non-secretory, aggressive behavior and frequently grows in the gastrointestinal and genitourinary tracts [1]. The median survival of patients with this disease who have distant metastases is about five months.”
“As a rule, an undifferentiated cancer is more malignant than a cancer of that type which is well differentiated.”